Page last updated: 2024-08-17

aldosterone and cilnidipine

aldosterone has been researched along with cilnidipine in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aritomi, S; Enomoto, A; Koganei, H; Konda, T; Niinuma, K; Nitta, K; Ogawa, T1
Arakawa, K; Fujii, M; Inoki, I; Kimura, T; Konoshita, T; Makino, Y; Miyamori, I; Nakamura, H; Wakahara, S1
Aritomi, S; Konda, T; Yoshimura, M1
Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y1
Ichihara, A; Itoh, H; Nishimura, T; Sekioka, R; Tanaka, M1
Fujii, M; Ichikawa, M; Imagawa, M; Ishizuka, T; Kaeriyama, S; Konoshita, T; Makino, Y; Nakamura, H; Nakaya, T; Sato, S; Suzuki, J; Urabe, M; Wakahara, S; Yamada, M; Yamamoto, K; Zenimaru, Y1

Trials

2 trial(s) available for aldosterone and cilnidipine

ArticleYear
A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.
    Journal of hypertension, 2010, Volume: 28, Issue:10

    Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin I; Angiotensin II; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; Dose-Response Relationship, Drug; Female; Humans; Hypertension; Male; Middle Aged; Renin; Renin-Angiotensin System

2010
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
    Heart and vessels, 2013, Volume: 28, Issue:4

    Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Creatinine; Dihydropyridines; Down-Regulation; Fatty Acid-Binding Proteins; Female; Humans; Hypertension; Japan; Linear Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome

2013

Other Studies

4 other study(ies) available for aldosterone and cilnidipine

ArticleYear
Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm.
    American journal of nephrology, 2009, Volume: 30, Issue:2

    Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Conotoxins; Dihydropyridines; Humans; Male; Norepinephrine; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; Time Factors

2009
L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action.
    Heart and vessels, 2012, Volume: 27, Issue:4

    Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Disease Models, Animal; Down-Regulation; Hypertension; Injections, Intravenous; Male; Nifedipine; Rats; Rats, Inbred SHR; Reflex; Renin-Angiotensin System

2012
Effects of cilnidipine on sympathetic nerve activity and cardiorenal function in hypertensive patients with type 2 diabetes mellitus: association with BNP and aldosterone levels.
    Diabetes research and clinical practice, 2014, Volume: 106, Issue:3

    Topics: Aged; Aged, 80 and over; Aldosterone; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Renin-Angiotensin System; Sympathetic Nervous System

2014
On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Bioscience reports, 2016, Volume: 36, Issue:5

    Topics: Aged; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Valsartan

2016